Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

tion with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company may experience delays in clinical trial patient enrollment, the risk that future clinical trial results may not correlate with the results of prior clinical trials and preclinical studies, the risk that Avid's revenue growth may slow or decline, the risk that future protocol submissions may not be approved, the risk that the company may not be able to monetize any of its assets, the risk that the company will not regain compliance with the Nasdaq Stock Market minimum bid price requirement by July 21, 2008, and the risk that the company will not have additional high profile scientific publications and presentations. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, ... diversified life sciences company, today announced that its stockholders ... of common stock of the Company from 1,000,000,000 to ... July 27, 2015 at the Law Offices of Nixon ... the Special Meeting, there were 480,655,929 shares of common ...
(Date:7/28/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... to German life sciences entrepreneurs with a proven ... biotechnology (collectively, the "Optionee"), an option to license ... technology (the "Technology"), including AEZS-120, the most advanced ... to enter a Phase 1 clinical trial. This ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, 2015 /PRNewswire/ ... health care services and one of the largest ... that its parent company and sole stockholder, Capella ... Medical Properties Trust, Inc. ("MPT") (NYSE: MPW ... cash.  The transaction is expected to be finalized ...
(Date:7/27/2015)...   Inocucor Technologies Inc ., the agriculture ... farmers, has received a notice of allowance from ... patent application to protect Inocucor consortia and unique ... yields on farms and in greenhouses. ... microbial consortium and its fermentation byproducts, which are ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... Indian company to purchase, distribute US-made bulk ... Specialty chemicals,maker Albemarle Corporation (NYSE: ... anti-inflammatory agent ibuprofen and other active pharmaceutical,ingredients ... pharmaceutical,company Dr. Reddy,s Laboratories Ltd. As per ...
... ST. JOSEPH, Mich., July 8 GeneGo, Inc., ... Keck Microarray Center,at Yale has become a certified ... access to GeneGo,s MetaCore, training and advanced,support., ... (Keck Lab),one of the largest biotechnology laboratories of ...
... market and business intelligence company, the enzyme market is significant ... 6.5 to 10%. Enzymes are sold in many different industry segments. ... , ... Paris (PRWEB) July 8, 2008 -- According ...
Cached Biology Technology:Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 2CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 3
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... April 14, 2013) Through a collaborative genome-wide study ... that are associated with heart rate. Since heart ... could provide a better understanding of genetic regulation of ... targets for new drugs to treat cardiovascular disease. ...
... 14, 2013)Drug-eluting stents can keep clogged leg arteries ... being presented at the Society of Interventional Radiology,s ... "Peripheral arterial disease (or PAD) is becoming increasingly ... obesity and diabetes epidemics," said Robert A. Lookstein, ...
... Injury: Latest News on Clinical Trials of Interventions to ... 17, 2013, from 4:30 to 6:30 p.m., at Kessler ... special Grand Rounds is presented by the Northern New ... Cord Injury Project of the W. M. Keck Center ...
Cached Biology News:Mount Sinai study identifies new gene variations associated with heart rate 2Drug-coated stents prevent leg amputation 2The State of Spinal Cord Injury Grand Rounds 2
... at the 9, 10, 12, and 13 positions. ... standard for the quantification of 13(S)-HODE by GC- ... of linoleic acid with plant and mammalian lipoxygenases. ... of tumor cells to the endothelium at concentrations ...
...
...
...
Biology Products: